An intriguing development is an ErbB3-targeting antibody-drug conjugate, U3-1402, which has shown encouraging activity in ErbB3-overexpressing breast cancer and EGFR-mutant, EGFR inhibitor-resistant non-small cell lung cancer and would be of interest in combination with cetuximab in HNSCC [36,37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.